Skip to content
TrackPodcasts
newsSep 18, 202522:31pending

Wary pharma: AstraZeneca sours on UK

About this episode

Pharmaceutical giant AstraZeneca has paused a £200m investment in Britain and could move its primary listing to America. Can the UK maintain its status as a “life-science superpower”? Why autonomous air wings are the future of war in the sky. And how scientists in the Caribbean are restoring the barrier reef through “coral IVF”. 


Listen to what matters most, from global politics and business to science and technology—Subscribe to Economist Podcasts+


For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.


Hosted on Acast. See acast.com/privacy for more information.

Get every episode summarized

Each time The Intelligence from The Economist publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.

Email me new episodes

Free for 3 shows. No card needed.

Hosts & guests

No transcript yet

This episode has not been transcribed. Request it and it moves to the front of the queue.

Wary pharma: AstraZeneca sours on UK

The Intelligence from The Economist

0:00
22:31

More episodes

More from The Intelligence from The Economist

View all episodes →